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ABSTRACT
Nucleic acid aptamers, especially RNA, exhibit valu-
able advantages compared to protein therapeutics
in terms of size, affinity and specificity. However,
the synthesis of libraries of large random RNAs
is still difficult and expensive. The engineering of
polymerases able to directly generate these libraries
has the potential to replace the chemical synthe-
sis approach. Here, we start with a DNA polymerase
that already displays a significant template-free nu-
cleotidyltransferase activity, human DNA polymerase
theta, and we mutate it based on the knowledge of its
three-dimensional structure as well as previous mu-
tational studies on members of the same polA fam-
ily. One mutant exhibited a high tolerance towards
ribonucleotides (NTPs) and displayed an efficient ri-
bonucleotidyltransferase activity that resulted in the
assembly of long RNA polymers. HPLC analysis and
RNA sequencing of the products were used to quan-
tify the incorporation of the four NTPs as a function
of initial NTP concentrations and established the ran-
domness of each generated nucleic acid sequence.
The same mutant revealed a propensity to accept
other modified nucleotides and to extend them in
long fragments. Hence, this mutant can deliver ran-
dom natural and modified RNA polymers libraries
ready to use for SELEX, with custom lengths and
balanced or unbalanced ratios.
INTRODUCTION
In the field of therapeutic biotechnologies, nucleic acids
have proved to be a useful tool for the regulation of gene
expression, medical diagnostics, biological route modula-
tion, molecular recognition strategies or drug design. Key
strategies have been developed and have proved their effi-
ciency for several years such as antisense nucleic acids (1,2),
ribozymes and riboswitches (3,4) and aptamers (5,6). How-
ever, some innovative breakthrough in the generation of
aptamer-based molecules remains needed to compete with
medicinal chemistry and/or biological antibodies.
Nucleic acid aptamers consist of single-stranded DNA
(ssDNA) or RNA that present defined 3D structures due to
their propensity to form complementary base pairs, Hoog-
steen base pairs, base triples or G-quartets. Their ability
to fold into various secondary and tertiary structures (7)
opens the possibility to design molecules that are capable
of specific molecular recognition of their cognate targets.
RNA aptamers are prone to generate more complex 3D
structures than DNA aptamers and usually display a higher
binding affinity and specificity (6). Van der Waals forces,
hydrophobic and electrostatic interactions, triple base-pairs
and base stacking all combine to generate folded struc-
tures and shielded active sites that determine their bind-
ing affinity and specificity. For all of these purposes, ap-
tamers are listed among the most important classes of drug
molecules and their development is facilitated by Systematic
Evolution of Ligands by EXponential enrichment (SELEX)
strategies (8,9). This efficient method of producing high-
affinity aptamers relies on the generation of a combinato-
rial library of oligonucleotides. These libraries must contain
a huge pool of random-sequence oligonucleotides to max-
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imize the chances to select good candidates. As an alterna-
tive to the chemical synthesis of random oligonucleotides at
the first step of aptamer selection, the engineering of DNA
polymerases designed to synthesize nucleic acids (RNA and
DNA) in a random fashion may provide a faster way to gen-
erate the initial libraries.
In vivo, DNA polymerases are responsible for the DNA
replication and the maintenance of the genome and there-
fore their role is critical for the propagation of the ge-
netic information. All DNA polymerases found in eukary-
otes, prokaryotes, archaea and viruses have been classi-
fied into subfamilies according to their structure and pri-
mary sequence similarity (10–12). By construction, replica-
tive DNA polymerases have evolved to copy the template
DNA with high fidelity and consequently their native ac-
tivity is of limited use for applications in modern synthetic
biology, which seeks to build novel and versatile nucleic
acid polymers. Indeed, DNA polymerases have an active
site that is configured to incorporate the four canonical de-
oxyribonucleotides and to exclude ‘altered’ or modified nu-
cleotides during cellular metabolism. However, the design
of mutants based on the known three-dimensional structure
of a DNA polymerase, if available, has the potential to lead
to engineered enzyme(s) with the desired property in a rel-
atively straightforward way.
DNA polymerases are divided into several families, based
on sequence alignments (11,12). Classically, polA, polB,
polY and reverse transcriptases (RT) all share the same fold-
ing type, while polC and polX share a different one. Never-
theless, they all have the same kind of catalytic site, based on
the two-metal ion mechanism (13). To our knowledge, only
members of the polA and polX families display a significant
nucleotidyltransferase activity.
The first family of DNA polymerases that we will con-
sider here is polA. Representative members of family A with
a known crystal structure are Escherichia coli DNA pol (13)
and Thermus aquaticus DNA pol (14) in prokaryotes, and
phage T7 (15) DNA pol in viruses; in eukaryotes, several
members of the polA family have been solved: in human,
Pol  takes part in the repair of DNA double-strand-breaks
(DSB) in the alternative (Ku-independent) Non Homolo-
gous End Joining (alt-NHEJ) process (16,17), Pol  in the
repair of DNA crosslinks occurring during homologous re-
combination (18) and Pol  is involved in mitochondrial
DNA replication (19). Very recently, human Pol  has been
described to display a robust terminal transferase activity
that is apparent when it switches between three different
mechanisms (20,21). Indeed, human Pol  is able to perform
non-templated DNA extension, as well as instructed repli-
cation that is templated in cis or in trans of the DSB. The
same study revealed that the non-templated transferase ac-
tivity is enhanced in the presence of Mn2+ ions and can be
combined with templated extension on the 3′-end of a nu-
cleic acid primer. Furthermore, it was shown that human
Pol  could incorporate NTPs, leading to the synthesis of
polymers of RNAs, although with low yields.
The other family of DNA polymerases which has some
significant nucleotidyltransferase activity is the pol X fam-
ily, especially those involved in classical (Ku-dependent)
NHEJ in eukaryotes (Pol , Pol , and TdT) (22–24). This
activity is usually enhanced in the presence of divalent tran-
sition metal ions such as Mn2+. Among them TdT (Termi-
nal deoxynucleotidyl Transferase) is known to catalyze ef-
ficient, non-templated, random nucleotide addition at the
V(D)J junctions to increase the diversity of the adaptive im-
mune system repertoire (24). It was also recently shown that
TdT can, in some conditions, have an in trans templated ac-
tivity on a DNA synapsis (25,26). On top of this property,
previous studies revealed that TdT indiscriminately incor-
porates ribonucleotides (NTPs) and deoxyribonucleotides
(dNTPs) (27) but then fails to extend the primer beyond
4–5 ribonucleotides when the substrate sensed by the en-
zyme is no longer a DNA but an RNA. This observation
is compatible with the known crystal structure of murine
TdT which shows that the steric barrier close to the 2′ po-
sition of the incoming dATP sugar in pol  and , a ty-
rosine residue, is replaced by a glycine in pol  and Tdt
(28). However, engineering TdT to make it accept an RNA
primer seems quite a challenge, given that the conformation
of the primer is a B-DNA structure in the tertiary complex,
contrary to what would be favored for an RNA primer (A-
DNA). In other words, there seems to be no ‘gate’ to the ri-
bonucleotides in the catalytic site of TdT but rather one or
several ‘checkpoints’ in guiding the primer single-stranded
oligonucleotide.
Taken together, the availability of crystal structures of Pol
 and TdT as well as their known predisposition to perform
random nucleotides incorporation in a template-free man-
ner suggest the possibility to engineer them so as to make
them tolerate both NTPs and dNTPs, as well as other mod-
ified nucleotides, opening the way to create novel random
nucleic acid synthesizing machines.
Given previous studies on the engineering of the gate of
ribonucleotides in members of the polA family (29,30), it
looks like it should be possible to engineer pol  steric gate.
Also pol  was shown to be a very tolerant polymerase
across lesions (31). Here, we propose to improve the original
nucleotidyltransferase property of human DNA Pol  by ra-
tional design with the aim of widening as much as possible
the diversity of the nucleic acid analogs that it can incorpo-
rate and consequently sampling in a more extensive way the
stability, the affinity and the specificity of RNA aptamers.
Evolutionary and structural context for rational design of pol
theta mutants with new properties
DNA polymerases contain an active site with highly con-
served sequence motifs that are structurally superimpos-
able within each family. In the polA family, several studies
showed that most DNA polymerases share three highly con-
served regions, called motifs A, B and C, that are located in
the palm domain (10–12). Motif A contains a strictly con-
served aspartate at the junction of a -strand and -helix,
while motif C contains two carboxylate residues (Asp or
Glu) at a beta-turn-beta structural motif (10). In the case
of human pol  the catalytic conserved aspartate (D2330)
is located between 12 and 9 and is part of a strictly
conserved motif A (DYSQLELR) in the different polA
(Supplementary Figure S1). This catalytic aspartate cor-
responds to D610 in Thermus aquaticus Taq DNA poly-
merase I which interacts with the incoming dNTP through
a Mg2+ ion and stabilizes the transition state that leads to
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new phosphodiester bond formation (32). This sequence
motif (DYSQLELR) is exceptionally well conserved in A-
family polymerases and within the Pol I family as described
in the Supplementary Figure S1 for Human pol  (PDB:
4X0P), Human pol  (PDB: 4XVK), Human mitochon-
drial pol  (PDB: 3IKM), Plasmodium falciparum DNA pol
(PDB: 5DKT), Phage T7 DNA pol (PDB: 1T7P), Klenow
fragment of E. coli DNA pol I (PDB: 1D8Y), Bacillus
stearothermophilus DNA pol I (PDB: 1L3S) and T. aquati-
cus (Taq) DNA pol I (PDB: 1TAQ).
Previous studies in Taq DNA pol I showed that muta-
tion of the catalytic aspartate of Motif A (D610) completely
abolished the polymerase activity and was immutable (33)
while libraries of mutants targeted on the other 13 residues
(605 to 617) of motif A showed that some positions toler-
ated a wide spectrum of substitutions (A608, I614, R617).
Otherwise, the remaining residues tolerated mainly conser-
vative substitutions (Y611, E615). The residue S612 was
highly mutable and accepted substitutions that are diverse
in size and hydrophobicity while keeping WT-like activity.
Alignment of human pol  and Taq pol I sequences in Mo-
tif A (Figure 1A) illustrates the conservation of this Mo-
tif and displays the correspondence of the residues in Taq
pol I and pol  sequences (D610 corresponds to D2330,
D615 to D2335). E615 forms a hydrogen bond with Y671,
a residue located in helix O within the Motif B in the fin-
ger domain. From these early studies, we retain that the fol-
lowing positions are good candidates for site-directed muta-
tions: L2334, E2335, A2328 within the motif A and residue
Y2387 in motif B (corresponding to Y671 in Taq pol I).
We note in passing that in polB family, the steric gate is
located at the same place in Motif A as in polA (Y in the
DxxLSYPSII motif) and the same is true for the polY fam-
ily (30).
The crystal structure of the polymerase domain of pol
 (residues 1792–2590; PDB 4X0P) (16) reveals the same
right hand-like topology seen in the homologs from bacte-
ria and phages. The surface representation of pol  (Figure
1B) illustrates the organization of the polymerase in three
domains (fingers, palm and thumb) and a N-terminal ex-
onuclease domain. The DNA strand slides into the catalytic
site between the fingers and the palm domains where the
motif A residues makes the junction between the two parts.
When pol  is superimposed with the large fragment of Taq
DNA pol I (1QSY) (Figure 1c), both structures display the
same overall conformation. The spatial organization of the
catalytic site of human pol  is shown in Figure 1d with
the strictly three conserved carboxylates (D2330, D2540
and E2541) that chelate the essential catalytic metal diva-
lent ions. In the immediate proximity of the catalytic triad
the residue E2335 is facing the incoming nucleotide in close
proximity to the C2′ of the ribose of the incoming nucleotide
(ddATP), while its carboxylate group forms a hydrogen
bond with the residues Y2391 (Motif B), Q2475 (Motif 6)
and R2241 (TGR Motif). The residues E615 (1QSY) and
E2335 (4X0P) are oriented in a similar manner in all polA
structures around the incoming nucleotide and can interact
with its sugar moiety and this confirms that E2335 should
be one of the first positions to mutate. Nevertheless, both
site-directed mutagenesis and early systematic mutational
studies of Motif A noted that the best mutants, when suc-
cessful in incorporating one or several ribonucleotides, were
unable to add long stretches of RNA, namely to become a
DNA-directed RNA polymerase (29).
To transform Taq pol I into a true RNA polymerase, sev-
eral authors found that larger libraries and better ways to
screen them were needed, such as short-patch compartmen-
talized self-replication (spCSR) selection (34). In this way,
Taq pol I libraries were generated by mutating the residues
597–617 that include the nucleotide binding pocket and
the steric gate residue E615. Among the different Taq pol
I mutants, I614K and a multiple-site mutant called SFR3
(A597T, W604R, L605Q, I614T, E615G) acquired the abil-
ity to incorporate NTPs while no detectable primer exten-
sion by wt-Taq pol I was observed with NTPs. One of the
best obtained mutants, called AA40, was able to incorpo-
rate up to six NTPs in the presence of Mg2+ and up to
14 NTPs when Mn2+ was used instead of Mg2+. This mu-
tant involves four mutations located in (extended) Motif A:
E602V, A608V, I614M and E615G.
In light of the close similarity of the Motif A region of Taq
pol I and human pol  (Figure 1A), all these results suggest
to indeed focus on residue E2335 and the immediately close
one L2334. We also considered the residues located in the
proximal region of the nucleotide binding pocket (Y2387
and possibly Q2384, Y2391) and those found in mutant
AA40 of Taq pol I described above (P2322, A2328).
MATERIALS AND METHODS
Materials and reagents
All chemicals and reagents were purchased from Sigma
Aldrich (Saint-Quentin Fallavier, France) or Thermo Fisher
Scientifics (Courtaboeuf, France) and were of the highest
purity. The commercial enzymes T4 Polynucleotide kinase,
T4 DNA ligase and T4 RNA ligase 1 were obtained from
New England Biolabs (NEB). The enzymes used for the
nucleosides digestion, Benzonase® nuclease, Phosphodi-
esterase I from Crotalus adamenteus venom and alkaline
Phosphatase from bovine intestinal mucosa were purchased
from Sigma Aldrich.
Nucleotides analogs
The following nucleotides were purchased from Jena
Bioscience: 5-ethynyl-UTP, 2-aminopurine-ribonucleotide-
5′-triphosphate, 2′-O-methyl-CTP, 2′-O-methyl-ATP, ara-
CTP, ara-ATP, ε-ATP, 2′-fluoro-ATP, 2′-fluoro-CTP, 2′-
fluoro-UTP and 2′-fluoro-GTP.
The following ones were purchased from Trilink Biotech-
nologies: 5-methyl-UTP, ATP, CTP, UTP, GTP.
Protein purification
WT Pol  (residues 1792–2590) was expressed from the
pSUMO3 construct (obtained from S. Doublié & S. Wal-
lace, Addgene plasmid #78462) in BL21 CodonPlus (DE3)
RIPL cells (Agilent technologies). The expression was car-
ried out by autoinduction in Terrific broth EZMix™ supple-
mented with -lactose (2 g/l), D-glucose (0.5 g/l), glycerol (8
ml.l−1), 100 g.ml−1 of ampicillin and 50 g.ml−1 of chlo-
ramphenicol. Six liters of autoinducing medium were inoc-
ulated (starting OD600, 0.05) and the culture was grown for
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Figure 1. Structure of human pol  polymerase domain (residues 1792–2590). (A) Sequence comparison of the motif A of T. aquaticus (Taq) pol I (1TAQ)
and human pol  (4X0P): the non-mutable residue D610 is colored in red while the residues that tolerate a wide spectrum of substitution are displayed in
orange, green or blue according to their increasing tolerance of substitution. (B) Surface representation of human pol  (PDB 4X0P) showing the general
shape of a right hand with the three domains: the fingers domain in green, the palm domain in orange and the thumb domain in blue. The DNA primer
is inserted between the palm and the fingers domains, with its 3′ end in the catalytic site. The N-terminal exonuclease domain is displayed in yellow. (C)
Superposition of Taq pol I (1QSY) and human pol  (4X0P), with both enzymes shown in stick models. A zoom-in stereo view of the fingers domain
shows the residues E615 in pink (1QSY) compared to E2335 in blue (4X0P) in close proximity of the incoming nucleotide (ddATP, in yellow) facing the
DNA primers (in pink for 4X0P and in grey for 1QSY). (D) Ribbon diagram of the ddATP-Ca2+ structure of pol  (16) showing the environment of the
catalytic site. The strictly conserved carboxylates (D2330, D2540 and E2541) coordinating the essential divalent metal cations, the mutable residues (P2322,
A2328, L2334, E2335, Q2384, Y2387 and Y2391) are displayed as sticks of different colors. The incoming ddATP is showed in ball-and-stick model and
the ssDNA primer (3′-end) is showed in light pink while the Ca2+ ion is shown as a purple sphere.
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60 h at 20◦C, with saturated cultures reaching a final OD600
between 5 and 8. The following steps were performed at 4◦C.
Cells were harvested and resuspended at a ratio of 2.5–3
ml/g of cell pellet in lysis buffer (50 mM HEPES pH 7.4,
300 mM NaCl, 10% glycerol, 1 mM TCEP, 5 mM imida-
zole, 1,5% (v/v) IGEPAL C6-30, 5 mM CaCl2, PIERCE™
EDTA-free protease inhibitor tablets and Benzonase® nu-
clease 500 U. Cell lysis was performed by using French
press Cell-Disruptor at 20 000 psi. Following clarification
by ultracentrifugation at 17 000 rpm for 1 h, two steps
of column purification were performed. The supernatant
was applied to a Ni-NTA resin through a HisTrap HP col-
umn (GE Healthcare Life sciences) which was equilibrated
with buffer A (50 mM HEPES pH 7.4, 300 mM NaCl,
20 mM imidazole, 0.005% (v/v) IGEPAL C6-30, 1 mM
TCEP, 10% (v/v) glycerol), and eluted with a gradient to
500 mM of imidazole with buffer B (50 mM HEPES pH 7.4,
300 mM NaCl, 500 mM imidazole, 0.005% (v/v) IGEPAL
C6-30, 1 mM TCEP, 10% (v/v) glycerol). Fractions from
Ni-NTA chromatography containing Pol  were 2-fold di-
luted to decrease NaCl content using diluting buffer C (50
mM HEPES pH 7.4, 0.005% (v/v) IGEPAL C6–30, 1 mM
TCEP, 10% (v/v) glycerol). Then, the diluted fraction was
applied to Heparin affinity chromatography. The HiTrap
Heparin column (GE Healthcare Life sciences) was equili-
brated with buffer D (50 mM HEPES pH 7.4, 50 mM NaCl,
0.005% (v/v) IGEPAL C6-30, 1 mM TCEP, and 10% (v/v)
glycerol) and the fraction was eluted with a gradient to 2 M
of NaCl with buffer E (50 mM HEPES pH 7.4, 2 M NaCl,
0.005% (v/v) IGEPAL C6-30, 1 mM TCEP, and 10% (v/v)
glycerol). The protein fraction was then concentrated and
frozen rapidly in a liquid nitrogen bath prior to storage at
–80◦C.
Generation of mutants
Variant pol  constructs were generated by site-directed mu-
tagenesis by using the Quick-Change II XL kit (Agilent
technologies) and were purified following the previously de-
scribed protocol. The oligonucleotides used for the mutage-
nesis are listed in the supplementary Table S1.
Oligonucleotides
Oligonucleotides were purchased from Eurogentec with
RP-HPLC purity and dissolved in Nuclease-free water.
Concentrations were measured by UV absorbance using the
absorption coefficient ε at 260 nm provided by Eurogentec.
ssDNA primer radiolabelling
Oligonucleotides were labelled as follows: 40 M of ssDNA
primer (14-mer) were incubated with [ -32P] ATP (Perkin
Elmer, 3000 Ci.mM−1) and T4 polynucleotide kinase (New
England Biolabs) for 1 h at 37◦C in a total volume of 25
l. The reaction was stopped by heating the T4 polynu-
cleotide kinase at 75◦C for 10 min. 25 M of label-free ss-
DNA primer was added to the mix and heated for 5 min up
to 90◦C, and slowly cooled to room temperature overnight.
Radioactive nucleotidyltransferase assay
5 M of Pol  was incubated with 50 nM of 5′ (33) P-labeled
ssDNA in the presence of 5 mM of MnCl2 in a total volume
of 10 l of activity buffer (20 mM Tris pH 8, 150 mM NaCl,
10% glycerol, 0.01% IGEPAL C6-30, 0.1 mg.ml−1 BSA).
The reaction was started by addition of 500 M of canon-
ical or modified NTPs and stopped after 0–60 min at 42◦C
by adding 10 mM EDTA and 98% formamide. The prod-
ucts of the reaction were resolved by gel electrophoresis on
a 8% or 15% acrylamide gel and 8 M urea. The 0.4-mm wide
gel was run for 3–4 h at 40 V/cm and scanned by Storm 860
Molecular Dynamics phosphorimager (GE Healthcare).
Non-radioactive nucleotidyltransferase assay
Different nucleotides ratios were tested in order to ver-
ify that each canonical ribonucleotide was equally incor-
porated by the polymerase. 5 M of enzyme was incu-
bated with 500 nM of non-labelled ssDNA primer and a
ratio 1:1:1:1 of the four ribonucleotides (500 M each) or
with 500 M of ATP, CTP and GTP, and 5 mM of UTP
(1:1:1:10) or with 500 M of ATP, CTP and GTP and 2.5
mM of UTP (1:1:1:5) or 500 M of ATP and GTP and 2.5
mM of CTP and UTP (1:1:5:5). Additional mixtures were
prepared with ATP/CTP and UTP/GTP (500 M each).
The reaction was performed in the same activity buffer in
presence of 5 mM of MnCl2 in a total volume of 100 l.
Synthetic RNAs (5–80 g) were first cleaned-up by using
the RNA Clean & Concentrator™-5 kit (Zymo Research).
The clean-up was carried out in two steps to allow the pu-
rification of small RNA fragments of size between 17 and
200 nucleotides (nt) and at the same time large RNAs (>200
nt). Purified synthetic RNAs were then used immediately
for HPLC analysis, for RNA sequencing, for aptamer li-
brary construction or stored at –80◦C.
Hydrolysis of synthetic RNA to nucleosides and HPLC anal-
ysis
Synthetic RNAs obtained after non-radioactive ssDNA
primer extension were hydrolysed according to previous
protocol (33) with slight modification. The purified RNA
pool was treated with Benzonase®nuclease (20 U), Phos-
phatase alkaline (1 U), Phosphodiesterase I (0.05 U) in 50
l of digestion buffer (50 mM Tris–HCl pH 8, 1 mM MgCl2,
0.1 mg.ml−1 BSA). The mix was incubated at 37◦C for 3 h
and the digestion was carried out overnight at room tem-
perature to insure a total lysis. Ribonucleosides were then
cleaned-up by using a 10 000 MWCO Vivaspin®-500 cen-
trifugal concentrator (Sartorius) and centrifuging for 10
min at 4◦C. The filtrates were transferred to a 100 l-vial in-
sert tube to be further analyzed by HPLC. Analytical HPLC
were carried out on a reverse phase C18 column (Kromasil
100-5-C18, 150 × 4.6 mm, AIT France) using a linear gra-
dient of 0–20% of acetonitrile in 10 mM TEAAc (triethy-
lammonium acetate) buffer at a flow rate of 1 ml.min−1
over 15 min. A mixture of the four ribonucleosides (5 l
at 0.25 mM each in digestion buffer) was injected as stan-
dard. The linearity and reproducibility of the measurements
were checked by injecting, separately, two more samples
with 10 and 25 l. The UV molar extinction coefficients of
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each nucleoside-5′-monophosphate (32) at 260 nm (15040,
12080, 7070 and 9660 l.mol−1.cm−1 for pA, pG, pC and pU
respectively) were used to quantify the amount of bases in-
jected in the HPLC system.
TruSeq RNA library preparation and sequencing
We used 100 ng of total synthetic RNA and constructed
the sequencing libraries using the TruSeq Stranded mRNA
LT Kit (Illumina, RS-122-2101, San Diego, CA, USA) as
recommended by the manufacturer, except that the frag-
mentation step was omitted. All the reagents were added
to the reaction but the incubation at 94◦C was not per-
formed. The directional libraries were controlled on Bioan-
alyzer DNA1000 Chips (Agilent Technologies, #5067-1504,
Santa Clara, CA) and the concentration determined using
the QuBit dsDNA HS kit (Q32854, Thermo Fisher Scien-
tific). They were sequenced on an Illumina Hiseq 2500 se-
quencer using a HiSeq SR cluster kit v4 cBot HS (Illumina,
# GD-401-4001) and a HiSeq SBS kit v4 50 cycles (Illu-
mina, #FC-401-4002) in order to have around 50 millions
single end reads of 65 bases per sample.
Different bases compositions were tested before RNA se-
quencing. A pool of the four nucleotides at a ratio of 1:1:1:1
(500 M each, samples annotated as ‘N’) or with 500 M of
ATP, CTP and GTP, and 5 mM of UTP (ratio of 1:1:1:10,
samples annotated as ‘10U’) or with 500 M of ATP, CTP
and GTP and 2.5 mM of UTP (ratio of 1:1:1:5, sample
annotated as ‘5U’) or 500 M of ATP and GTP and 2.5
mM of CTP and UTP (ratio of 1:1:5:5, sample annotated
as ‘5U5C’).
Analysis of the sequencing reads
For each sample the quality of the reads was checked using
FastQC v0.11.5 and reads containing TruSeq adapters were
removed using cutadapt v1.14. Statistical analyses were per-
formed using R v3.3.2, Shortread v1.32.0 and Biostrings
v2.42.1
RESULTS
Efficient NTPs incorporation by unlocking the steric gate
residue of pol 
Human pol  WT has been already described to have the
ability to incorporate NTPs (20) in a template-free man-
ner from the 3′-end of a ssDNA or ssRNA primer, albeit
with a low yield. Therefore, human pol  is a good starting
point when compared to Terminal deoxynucleotidyltran-
ferase (TdT), where the elongation of NTPs stops after 5–6
additions (27).
With the aim of selecting the best human pol  mu-
tant with an enhanced incorporation of NTPs, we eval-
uated the ability of several mutants to elongate a ss-
DNA primer through a nucleotidyltransferase assay. One
or two-site directed mutagenesis were performed and led
to generate the following mutants: NM11 (Y2387F), CS13
(E2335G), GC10 (P2322V), DW9 (L2334M-E2335G) and
MC15 (A2328V). The nucleotidyltransferase activity was
first tested with dNTPs (Figure 2) and all the mutants tested
Figure 2. Deoxynucleotidyltransferase activity of human pol  WT and its
respective mutants. Denaturing 15% acrylamide gel showing the activity
of pol  variants in the presence of Mn2+ cations and each of the four
dNTPs (A, T, C, G) and the mix of all four dNTPs (N). A 14-mer ssDNA is
used as a primer. The primer extension of three mutants (NM11 (Y2387F),
CS13 (E2335G) and GC10 (P2322V)) are displayed in the same conditions
as the pol  WT. Reactions were stopped after 30 min by the addition of
formamide blue.
(NM11, CS13, GC10) retained the native activity as they
incorporated the four natural dNTPs and generated frag-
ments of length of up to 150 nt like the pol  WT in the pres-
ence of 5 mM of Mn2+. When dNTPs were replaced by each
NTP (ATP, UTP, CTP, GTP) the pol  WT showed results
similar to those previously described (20). ATP and GTP
(purine bases) are well tolerated by pol  WT and medium-
length homopolymers of A and G (up to 50–70 nt) were
obtained. UTP and CTP were incorporated but the elonga-
tion stopped after a few additions. The mutants NM11 and
GC10 were unable to incorporate more than three or four
NTPs. On the contrary, the mutant CS13 was particularly
efficient as >50 of each ribonucleotide were readily incor-
porated, except for UTP that formed homopolymers whose
length reached only up to 15 nt, still longer than the pol
 WT would add. Furthermore, when the four NTPs were
mixed together the elongation was clearly enhanced com-
pared to the wild-type enzyme, in that 100% of the primer
were extended and the synthesized heteropolymers reached
more than 150 nt in 30 min (Figure 3a). Mutants DW9
and MC15 were also tested for their incorporation rate of
NTP: MC15 did not show better efficiency than the wild-
type while DW9 showed an efficiency comparable to CS13
mutant. Overall, the best mutants are CS13 and DW9 which
both carry the E2335G mutation, with a significantly im-
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Figure 3. Ribonucleotidyltransferase activity of human pol  WT and its respective mutants. (A) Denaturing 15% acrylamide gel showing the activity of
pol  variants in the presence of Mn2+ cations and each of the four NTPs (A, U, C, G at 0.5 mM each) and the mix of all four NTPs (N, at 0.5 mM each). A
14-mer ssDNA is used as a primer. The primer extension of five mutants: NM11(Y2387F), CS13 (E2335G), GC10 (P2322V), MC15 (A2328V) and DW9
(L2334M-E2335G) are also displayed in the same conditions as the pol  WT. Reactions were stopped after 30 min. (B) Time-course of the elongation of
a 14-mer ssDNA primer by CS13 mutant in the presence of a stoichiometric mix of the four NTPs (0.5 mM each) and separated in a 8% acrylamide gel.
At each indicated time (0 s to 60 min), the reaction was stopped by the addition of formamide blue.
proved substrate specificity towards ribonucleotides and an
enhanced capability to promote RNA extension compared
to the pol  WT.
In the perspective of generating a library of random se-
quences of RNA with controlled fragment lengths the ki-
netics of primer extension was studied in the same condi-
tions and allowed to monitor the length of the products as
a function of the reaction time. In the case of 20–30 nt RNA
fragments, 1 min-reaction is sufficient to complete the syn-
thesis (Figure 3B).
Structural rationale of incorporation of ribonucleotides by
CS13 mutant
CS13 mutant consists in the substitution of the charged
glutamate residue E2335 by the small and flexible glycine
amino-acid. The steric gate residue E2335 is located in close
proximity to the sugar moiety of the incoming nucleotide.
In the case of ddATP-pol  structure (PDB 4X0P) the
carboxylate group of the glutamate contributes indirectly,
through its interaction with Y2387, to the positioning of
the nucleotide (Supplementary Figure S2A). In the case of
NTP, the presence of the hydroxyl group at the C2′ po-
sition creates both steric hindrance and electrostatic con-
straints between the sugar moiety and the pocket shaped by
the residues E2335, Y2387 and Y2391 (Figure 1D and Sup-
plementary Figure S2B). The mutation E2335G obviously
enlarges the nucleotide binding pocket and is indeed com-
patible with an increased ability to incorporate a ribonu-
cleotide into the 3′-end of the ssDNA primer (Supplemen-
tary Figure S2C). Similar observations were described for
E. coli phage T7 DNA polymerase, where the ribose moiety
of the incoming nucleotide is lodged between the aromatic
ring of the residue Y526 and the aliphatic carbons of the
E480 side chain, which itself is hydrogen-bonded to the hy-
droxyl of the strictly conserved Y530 (15). The spatial ori-
entation of these residues forms a hydrophobic pocket at
the C2′ position of the ribose that might exclude ribonu-
cleotides from the active site, thus providing a structural
basis for the strong discrimination against ribonucleotide
incorporation by this DNA polymerase.
To understand how long RNA synthesis can occur in the
CS13 mutant, we analyzed the primer strand conformation
and residues in contact with it in pol , and compared it
with the closed form of KlenTaq (PDB 3KTQ). Three out of
four copies of the 4X0P pol  structures superimposed very
well, and also to KlenTaq, where the DNA is in a mixed A-
B form, which would be compatible with binding an RNA
strand. In addition, we found that two loops in close con-
tact with the DNA in KlenTaq were either remodeled (586–
589 in 3KTQ, 2254–2256 in pol ) or longer and disordered
(504–513 versus 2145–2175), possibly giving more confor-
mational freedom to the DNA or RNA primer substrate in
pol  compared to KlenTaq, while still holding it with a very
tight grip.
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Quantifying the amount of incorporation of the four ribonu-
cleotides by CS13 mutant
The success of a SELEX method relies on the quality of
the initial nucleic acids library. Therefore, the possibility to
have access to a large collection of random-sequence RNA
or DNA fragments is essential. The CS13 mutant demon-
strated, as assessed by gel electrophoresis, a remarkable abil-
ity to elongate a DNA primer with ribonucleotides, but in
these experiments the proportions of incorporation of the
four NTPs are unknown. We used HPLC analysis in or-
der to quantify the overall base composition of the newly
synthesized RNAs. Prior to HPLC separation the RNAs
were completely digested into ribonucleosides according to
a published protocol (35).
First a calibration of the method was performed: the
chromatogram of the standards solutions of the four ri-
bonucleosides at a final concentration of 0.25 mM in the
digestion buffer indicated four peaks eluting at 5.60, 6.36,
7.82, 9.74 min respectively for cytidine, uridine, guano-
sine and adenosine (Figure 4A). The injected mix of stan-
dard nucleosides (in equal proportions) resulted in a global
composition of 27.9%mol C, 22.5%mol G, 23.8%mol A and
25.8%mol U calculated from the UV extinction coefficient
of each nucleoside-5′-monophosphates according to previ-
ous studies (35,36).
The denaturing gels of the products generated by the
CS13 mutant (Figure 3A) indicated that in presence of an
equal proportion of the four NTPs (1:1:1:1 at 0.5 mM each),
long polymers of RNA were synthesized but they give no
indication on the distribution of each nucleoside along the
sequence. However, the incorporation of each of the four
NTPs into homopolymers displayed different trends, espe-
cially UTP which seemed to be integrated less efficiently by
the enzyme in the context of poly-U. To measure the propor-
tion of nucleosides in long heteropolymers synthesized by
CS13, the reaction products obtained by an initial mixture
containing NTPs (1:1:1:1) were cleaned up and hydrolyzed,
and the resulting ribonucleosides were analyzed by HPLC
(Figure 4B). We found that the initial mix of 1:1:1:1 NTPs
gave 24.8%mol C, 24.6%mol G, 22.1%mol A and 28.6%mol U
in the generated polyribonucleotides, on average.
In addition, another synthesis condition was prepared
that contained a tenfold molar excess of UTP (1:1:1:10) and
analyzed in the same way (Figure 4). Again, four peaks were
observed, corresponding to the retention time of the four
nucleosides, but the calculated peak areas of each compo-
nent revealed different distributions (Supplementary Table
S2). We found that the initial mix of 1:1:1:10 NTPs gave
7.6%mol C, 9.0%mol G, 7.6%mol A and 75.9%mol U.
When the equimolar combination of only two NTPs
(A/C; Figure 4D and U/G; Figure 4E) an approximately
equal probability of incorporation of both substrates was
obtained for C and A (55.8%mol C, 44.2%mol A) and for G
and U (51.9%mol G, 48.1%mol U).
These results suggest the possibility to modify the initial
substrates composition in order to modulate the incorpo-
ration of one or several specified nucleotide(s) in the final
products. On average, it appears that CS13 mutant accepts
the four natural NTPs with about the same efficiency.
Evaluation of the random character of the library of ssRNA
generated by CS13 mutant
Next, the sequencing of RNA products was performed in
order to reveal more details about the ribonucleotides in-
corporation by the mutant CS13. For the different condi-
tions tested the RNA library displayed up to 31 millions of
reads. For the whole library, the occurrence of the differ-
ent sequences was estimated and was plotted as illustrated
in Figure 5. Among 27 386 038 reads in the sample ‘N’, 18
626 379 reads had unique sequence (occurrence = 1), rep-
resenting almost 68% of the total reads in the library (Fig-
ure 5A). The rest is dispersed between 2 (3 271 687 other
reads with sequences repeated twice) and 111 670 occur-
rences (one sequence). To evaluate the distribution of the
nucleotides along each sequence, we analyzed the propor-
tion of the four nucleotides at each incorporation cycle (Fig-
ure 5B). The sequencing has been performed for the 65 first
bases of each RNA fragment, and all the 65 positions of the
27 386 038 reads were taken in to account after cleaning the
sequences from the DNA primer (14-mer) used for the elon-
gation. The results indicate that when the four nucleotides
were mixed at an equimolar ratio (sample ‘N’), a roughly
equal incorporation is observed for the RNA synthesis by
the CS13 mutant. Within the 65 cycles, the global propor-
tion of added nucleotide remained constant up to position
50 with a value of 26.7%, 25.0%, 24.0% and 24.3% for A,
C, G and U, respectively (Figure 5B). Additionally, the his-
tograms representing the frequency of each nucleotide dis-
play an approximately Gaussian shape (Figure 5C).
Furthermore, it is possible to estimate from the data the
probability P(j | i) of adding one (A/C/G/U) nucleotide (j)
in position N after a given nucleotide (i) in position N – 1.
This quantity can then be used to test whether or not the na-
ture of the added nucleotide in position N depends on the
nature of the nucleotide present at the position N – 1. At
first sight, there are indeed differences among the 16 possi-
ble dinucleotides, as, for instance, GC is the most probable
occurrence when an equimolar ratio of ribonucleotides is
present, while, to the opposite, it is less probable to form
UC and GG dinucleotides in the same conditions (Figure
6a). We compare P(j | i) to P(j) by calculating their con-
cordance correlation coefficient and find 0.252, 0.229 and
0.280 in three different replicates, meaning that the infor-
mation on nucleotide frequencies is not enough to explain
dinucleotide frequencies. These numbers change very little
if one restricts the analysis to unique sequences, i.e. single
reads (0.239, 0.226 and 0.278).
We next used information on tri-nucleotides P(k | j, i), the
probability of observing nucleotide k at position N, given
that nucleotide j is observed at position N – 1 and nucleotide
i at position N – 2 and compare it to P(k | j). The con-
cordance correlation coefficient between these two values
is 0.776 (Figure 6B), 0.766 or 0.779 in three different repli-
cates, indicating that most (but not all) of the information
contained in trinucleotide (i, j, k) conditional frequencies
is already contained in the knowledge of the dinucleotide
(j, k). These numbers change very little if one restricts the
analysis to unique sequences only (0.776, 0.769 and 0.781).
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Figure 4. HPLC separation and quantification of the ribonucleosides obtained after enzymatic hydrolysis of synthesized RNAs. (A) Chromatogram of
the standard solutions of the four ribonucleosides (adenosine, guanosine, uridine and cytidine at concentrations of 0.25 mM each in the digestion buffer,
the retention times and the base corresponding to each peak are displayed on top of each peak. (B) RNA hydrolysate obtained from RNA synthesis by
CS13 and an equimolar mix of the four NTPs (C) RNA hydrolysate obtained from RNA synthesis by CS13 and a mix containing ATP/CTP/GTP/UTP
at a molar ratio of 1:1:1:10. (D) RNA hydrolysate obtained from RNA synthesis by CS13 and an equimolar mix of ATP and CTP. (E) RNA hydrolysate
obtained from RNA synthesis by CS13 and an equimolar mix of GTP and UTP. UV detection at 260 nm was used.
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Figure 5. Statistical analysis of random RNAs synthesized by CS13 mutant. (A) Occurrences of the reads illustrated by a log–log scatter plot chart.
Condition ‘N’ represent RNA synthesis by CS13 and the mix of four nucleotides at a ratio of 1:1:1:1 (500 M each). (B) Nucleotide proportion per
incorporation cycle illustrated by a stacked bars chart for the same sample ‘N’. (C) Frequency of each number of nucleotides of type A, C, G or U per
read, represented by a histogram.
Modified nucleotides incorporation by the CS13 mutant
One of the main drawbacks of aptamers is their relative
instability and their sensitivity to hydrolysis in biological
fluids. The solution to overcome this point is to produce
nuclease-resistant RNA molecules by different approaches
(5,37,38). Modifications can be grafted on the nucleotide
sugar moiety, the phosphodiester covalent link or on the
base.
The incorporation of modified ribonucleotides has been
also investigated for the CS13 mutant in comparison
with pol  WT. The following analogs were tested: 2′-
fluoro-dUTP, 2′-fluoro-dATP, 2′-fluoro-dCTP, 2′-fluoro-
dGTP, 2′-fluoro-dTTP, 2′-amino-dATP, 2′-amino-dCTP,
2′-amino-dGTP, 2′-amino-dTTP, 2′-O-methyl-dATP, 2′-O-
methyl-dCTP, 2′-O-methyl-dGTP, 2′-O-methyl-dTTP, 2′-
N3 -dATP, 2′-N3 -dCTP, 2′-N3 -dGTP, 2′-N3 -dTTP, ara-
ATP, ara-CTP, ε-ATP and 2-aminopurine rTP.
It has been described that the incorporation rate of 2′-
fluoro-modified ribonucleotides by T7 RNA polymerase
was ten-fold lower than that of the natural substrates
(37). The templated incorporation of 2′-fluoro modified nu-
cleotides by DNA polymerases were already assessed in sev-
eral studies and found to be low (38), so that the incorpo-
ration of these modified nucleotides by enzymatic synthesis
remains relatively limited compared to chemical synthesis.
Here, we found that all the 2′-fluoro (Figure 7, lanes 16–21)
were incorporated by CS13 mutant in the same experimen-
tal conditions as the primer extension by natural NTPs, with
a much greater efficiency than pol  WT. This modification
is suitable for ribozyme development and aptamers selec-
tion as the 2′-fluoro-modified oligonucleotides have better
ribonucleases resistance (39–41).
The CS13 mutant failed to elongate the ssDNA primer in
presence of 2′-O-methyl modified nucleotides further than
just a few nucleotides (Figure 7, lanes 6–10). 2′-O-methyl-
modified RNA display better stability against hydrolysis
by ribonucleases as well as increased Tm values. This at-
tribute may be useful to preserve the 3D conformation and
to widen the diversity of a functional aptamers (42). Thus,
the acceptance of 2′-O-methyl modified nucleotides need to
be improved with CS13 mutant, perhaps by introducing a
second mutation at residue 2334 with a non-hydrophobic
residue (43).
The incorporation of 2′-amino dATP and 2′-amino
dGTP (Figure 7, lane 1–5) appeared to be quite efficient
with the CS13 mutant, more than 2′-amino dTTP and 2′-
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Figure 6. Further statistical analysis of random RNAs synthesized by CS13 mutant. (A) Nucleotide transition matrix illustrating the proportion of
A/C/G/U added after a given nucleotide, shown as a horizontal stacked bars chart for the condition ‘N’, which is the mix of four nucleotides at a ratio of
1:1:1:1 (500 M each). (B) Scatter plot showing the correlation between the 64 trinucleotide frequencies P(k | j, i) as a function of each 16 P(k | j) frequency.
amino dCTP. For 2′-N3 dNTP, the incorporation was very
good with the mutant CS13, almost as good as the 2′-F
derivatives, allowing the possibility to perform click chem-
istry experiments with compounds containing an alkyne
group (lanes 11–15).
9--D-Arabinofuranosyladenine (ara-ATP), an an-
tiviral drug against Herpes simplex virus (44) and
1-arabinofuranosylcytosine (Ara-CTP), an analogue
of pyrimidine used in cancer chemotherapy (45), were
also tested but the incorporation appeared to be very
weak (Figure 7, lanes 22–24). Finally, two fluorescent ana-
logues of adenine nucleotides were tested: etheno-adenine
(Figure 7, lane 25) and 2-aminopurine (lane 26). Both
were incorporated by CS13 mutant but formed only short
polymers.
DISCUSSION AND PERSPECTIVES
To our knowledge, no RNA or DNA polymerase has been
described to operate as a template-free ribonucleotidyl-
transferase and to synthesize long random RNAs. Since hu-
man DNA polymerase  exhibits a versatile range of activi-
ties, including the capability to elongate nucleic acid primers
without template requirement and to incorporate modified
nucleotides (20,46) we took up the challenge of developing
it into an RNA synthesizing machine. Among other mem-
bers of the pol A family, the replicative human mitochon-
drial DNA polymerase  has been described to incorporate
NTPs both in vivo and in vitro, to maintain DNA replica-
tion when the dNTPs pool is poor (47) but this was in the
presence of a DNA template.
On the basis of available structural information, we ob-
tained two pol  mutants, CS13 and DW9, that demon-
strated a reliable ability to perform RNA random synthesis
and to incorporate several other modified nucleotides. The
randomness of the synthesized sequences and the Markov
Model behind it have been assessed quantitatively and this
new enzymatic activity should be useful for therapeutics
applications. In that way, the continuous quest for ultra-
effective, selective and non-toxic nucleic acids-based drugs
might be pursued using optimized aptamer design strate-
gies. Indeed, our work offers a viable biological alterna-
tive to the generation of RNA random sequences by chem-
ical synthesis and library design. By establishing an effi-
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Figure 7. Incorporation of modified nucleotides by pol  WT in comparison with the pol  CS13. The following nucleotide analogs were tested for the
elongation of a ssDNA primer by pol  CS13 compared to pol  (1) 2′-amino-dATP, (2) 2′-amino-dUTP, (3) 2′-amino-dCTP, (4) 2′-amino-dGTP, (5)
mix of 2′-amino-dATP/dUTP/dCTP/dGTP, (6) 2′-O-methyl-dATP, (7) 2′-O-methyl-dUTP, (8) 2′-O-methyl-dCTP, (9) 2′-O-methyl-dGTP, (10) mix of 2′-
O-methyl-dATP/dUTP/dCTP/dGTP, (11) 2′-azido-2′-dATP, (12) 2′-azido-2′-dUTP, (13) 2′-azido-2′-dCTP, (14) 2′-azido-2′-dGTP, (15) mix of 2′-azido-
2′-dATP/dUTP/dCTP/dGTP, (16) 2′-fluoro-dATP, (17) 2′-fluoro-dUTP, (18) 2′-fluoro-dCTP, (19) 2′-fluoro-dGTP, (20) 2′-fluoro-dTTP, (21) mix of 2′-
fluoro-dATP/dUTP/dCTP/dGTP, (22) Ara-ATP (vidarabine triphosphate), (23) Ara-CTP (cytarabine triphosphate), (24) mix of Ara-ATP and Ara-CTP,
(25) ε-ATP, (26) 2-aminopurine riboside triphosphate. The reactions were performed in the same conditions as the natural NTPs in presence of Mn2+.
cient enzymatic SELEX procedure, the assay costs would
be reduced at the same time as the duration of the se-
lection cycle. Furthermore, human pol  does not require
toxic compounds (such as cacodylate buffer, cobalt divalent
ions, which are needed for TdT) to operate RNA or RNA
analogs synthesis, thereby conferring safer alternatives to
library construction and biotechnological applications.
To make this work complete, it will be necessary to de-
velop an efficient method of amplification of a set of selected
sequences from the aptamer library, i.e. the pool of synthe-
sized RNAs. As a matter of fact, SELEX procedure com-
prises a step where the aptamer candidates need to be am-
plified before the next selection step. In our case, the newly
synthesized RNAs do not have a fixed 3′ region, which is
necessary for their amplification by PCR. Our next goal is
to enzymatically add a fixed sequence at the 3′ end of each
RNA fragment (the 5′ end contains the constant known
primer sequence). Thus, the resulting pool of RNAs would
be suitable for self-amplification, possibly by using the same
enzyme, human pol  CS13. By doing this, it would be pos-
sible to execute the entire SELEX procedure in an all-in-
one system. In some preliminary tests, we performed a lig-
ation of a fixed fragment to each synthesized RNA by ex-
ploiting T4 RNA ligase I activity. The preliminary results
are encouraging and indicate that the ligation of these fixed
oligonucleotides indeed occurs with our protocol. It is now
necessary to optimize the experimental conditions to ensure
100% of ligation.
We also showed that human pol  CS13 mutant accepted
modified nucleotides with different efficiencies. Recent stud-
ies already described that human pol  was able to in-
corporate nucleotides analogs better than the DNA poly-
merases TdT, Pol 	 or Pol 
, which are also error-prone and
show some ability to incorporate nucleotide analogs. For in-
stance, base analogs conjugated on position 5 of the pyrim-
idine moiety by fluorescent compounds (20) (Cy3-dUTP,
Texas Red-5-dCTP, Biotin-16AA-dUTP) or large benzo-
expanded nucleotides (45) were found to be incorporated
by pol . Here we show that ε-ATP and 2-aminopurine
rTP that are intrinsically fluorescent, can be incorporated
to some extend by CS13 mutant of human pol . It would
be interesting to determine whether if it would be possible
to control the addition of these analogs at the end of RNA
fragments for specific applications such as nucleic acid la-
belling for cell imaging, click-chemistry or, improved target
binding.
It should be mentioned here that Romesberg and coll.
(48) managed to develop an engineered DNA polymerase
capable of amplifying directly RNA and modified RNA
such as 2′ fluoro RNA. Also, these authors developed a
third type of base pair that could be tried in the near
future to be incorporated by CS13 mutant (49). More-
over, DeStefano and colleagues (50) developed a SELEX
procedure that was suitable to select FANA aptamer to
HIV-1 reverse transcriptase (RT). Their work led to the
first FANA aptamers to HIV-1 Reverse Transcriptase (RT)
made by direct selection using all FANA nucleotides. The
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results demonstrated that XNA may be an excellent alter-
native for aptamer generation. Another example is illus-
trated by the work of S.A Benner (51) and colleagues who
generated aptamer libraries from a six-letter genetic alpha-
bet, that contain the standard nucleobases and two added
nucleobases (2-amino-8H-imidazo(1,2-)(1,3,5)triazine-4-
one and 6-amino-5-nitopyridine-2-one). From this artifi-
cially expanded genetic information system (AEGIS) 8 ap-
tamers were recovered after several rounds of selection on
proteins expressed on the surface of an engineered liver cell-
line.
The ability of Human pol  CS13 mutant to generate ran-
dom polyribonucleotides opens the way to a greater diversi-
fication of aptamer libraries. Not only larger pool of RNAs
can be produced, but also more diverse secondary structures
would be formed with modified nucleotides inserted along
each RNA fragment. In this way, the use of pol  CS13
could improve SELEX procedures and lead to the discovery
of more efficient and more specific therapeutic compounds.
In the immediate future, we will seek to make the proof-of-
principle of the use of pol  CS13 in a SELEX procedure by
selecting a known target, such as the thrombin, a classical
test-case (52,53).
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Sukumar,N., Rougeon,F. and Papanicolaou,C. (2002) Crystal
structures of a template-independent DNA polymerase: murine
terminal deoxynucleotidyltransferase. EMBO J., 21, 427–439.
29. Astatke,M., Ng,K., Grindley,N.D.F. and Joyce,C.M. (1998) A single
side chain prevents Escherichia coli DNA polymerase I (Klenow
fragment) from incorporating ribonucleotides. Proc. Natl. Acad. Sci.
U.S.A., 95, 3402–3407.
30. Brown,J.A. and Suo,Z. (2011) Unlocking the sugar “Steric Gate” of
DNA polymerases. Biochemistry, 50, 1135–1142.
31. Hogg,M., Seki,M., Wood,R.D., Doublié,S. and Wallace,S.S. (2011)
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